CD19/CD22-targeted Chimeric Antigen Receptor Engineered T Cell (CART) in B-Cell Acute Lymphoblastic Leukemia.

PHASE1/PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 1, 2017

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2025

Conditions

Leukemia, B-cell

Interventions

BIOLOGICAL

CART-19/22

Split intravenous infusion of CART-19/22 cells of (Dose escalating infusion of 1 - 20 x10\^6 CART-19/22 cells/kg).

Trial Locations (1)

RECRUITING

The First Affiliated Hospital of Soochow University, Suzhou

All Listed Sponsors

collaborator

The First Affiliated Hospital of Soochow University

OTHER

lead

Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd

INDUSTRY